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We investigated the antinociceptive and nerve excitability eﬀects of the N-salicyloyltryptamine (NST) NST-treated mice exhibited
a signiﬁcant decrease in the number of writhes when 100 and 200mg/kg (i.p.) were administered (i.p.). This eﬀect was not
antagonized by naloxone (1.5mg/kg, i.p.). NST inhibited the licking response of the injected paw when 100 and 200mg/kg
were administered (i.p.) to mice in the ﬁrst and second phases of the formalin test. Because the antinociceptive eﬀects could be
associated with neuronal excitability inhibition, we performed the single sucrose gap technique and showed that NST (3.57mM)
signiﬁcantly reduced (29.2%) amplitude of the compound action potential (CAP) suggesting a sodium channel eﬀect induced by
NST. Our results demonstrated an antinociceptive activity of the NST that could be, at least in part, associated to the reduction of
the action potential amplitude. NST might represent an important tool for pain management.
1.Background
In the past few decades, a number of studies have been
performed in an attempt to elucidate and understand
the factors and mechanisms involved in normal sensory,
pain perception and its treatment. However, although a
considerable number of analgesic drugs are available for
pain management, the search for the development of new
compounds as therapeutic alternatives continues as those
drugs present a wide range of side eﬀects [1].
Furthermore, Davies et al. [2]h a v er e p o r t e dt h eu s eo f
anticonvulsant and antidepressive drugs in the treatment
of chronic neuropathic or inﬂammatory pain. The anticon-
vulsant drugs are able to reverse or avoid seizures acting
by decreasing the neuronal response to seizure-induced
stimuli which are commonly used to treat pain disorders
[3]. These drugs have a role in its treatment due to the fact
that some clinical pain disorders seem to have common
physiopathogenic mechanisms with seizures [4]. In this way,
phenytoin and carbamazepine have been evidenced to exert2 Journal of Biomedicine and Biotechnology
an analgesic eﬀect on trigeminal neuralgia, glossopharyngeal
and occipital neuralgia [5, 6], and diabetic neuropathy [2].
N-Salicyloyltryptamine (NST) is a new analogue of N-
benzoyltryptamine synthesized in our laboratory (Patent
claimed, BR 200304393-A, [7]). Gutierrez et al. [8] showed
that Nb-benzoyltryptamine derivatives have relaxant activity
in guinea-pig ileum and Oliveira et al. [9] attributed
anticonvulsant properties to it. In preliminary behavioral
screening with NST, Oliveira et al. [10] showed a depressant
eﬀect on the CNS and anticonvulsant property in mice.
Thus, the aim of this study was to verify the antinocicep-
tive eﬀect of N-salicyloyltryptamine (NST), the tryptamine
analogue, using diﬀerent experimental models of nocicep-
t i o n ,a sw e l la st oi n v e s t i g a t ew h e t h e rs u c he ﬀect might be
involved in the nerve excitability through the single sucrose
gap technique.
2. Methods
2.1. Animals. M a l eS w i s sm i c e( 2 5 – 3 2 g )a n dm a l eW i s t a r
rats (250–300g) were used. All of them were obtained from
the Laboratory of Pharmaceutical Technology Animal Care
and were maintained at a controlled room temperature (21
± 2◦C) with food and water ad libitum,a sw e l la so na
12-h light/12-h dark cycle. All experiments were conducted
between 8 AM and 5 PM. Animals were previously habitu-
ated to the manipulations. Experimental protocols and pro-
cedures were approved by the Laboratory of Pharmaceutical
Technology Animal Care and Committee (no. 1105/06).
2.2. Drugs. For all in vivo experiments, the following drugs
were used: NST (Laboratory of Pharmaceutical Technol-
ogy, Brazil) (Figure 1), morphine hydrochloride (Crist´ alia,
Brazil), indomethacin (Sigma, USA), naloxone hydrochlo-
ride(Neoqu´ ımica,Brazil),37%formaldehyde(Vetec,Brazil),
and acetic acid (Vetec, Brazil). Vehicle was 5% Tween 80
(Sigma, USA) dissolved in 0.9% saline solution and used
to dilute the test drugs. In in vivo protocols, the agents
were injected intraperitoneally (i.p.) at a dose volume of
1mL/10g (mice). The physiologic solution used for the in
vitrotestswascomposedby(inmM):NaCl150;KCl4;CaCl2
2; MgCl2 1; glucose 10; [N-(2-hydroxyethyl)piperazine-N -
2-ethanesulfonic acid] (HEPES) 10, adjusted to pH 7.4 with
NaOH.
2.3. Acetic Acid-Induced Writhing. Initially, the mice were
divided into ﬁve groups (n = 10, each). Then, they were
pretreated with NST (100 and 200mg/kg, i.p.) or tween
80 solution (0.2%, i.p.), while positive control was treated
with morphine (5mg/kg, i.p.) 45min before an injection of
0.85% acetic acid (0.25ml/animal, i.p.). The doses of NST
applied in the present study were based on the study of
Oliveira et al. [10]. Each animal was isolated in an individual
observation chamber and 10min after acetic acid injection,
the cumulative number of writhing responses was recorded
during 15min [1, 11]. The eﬀect of pretreatment with
naloxone (1.5mg/kg, i.p., 30min before the algogen admin-






Figure 1: Molecular structure of the N-salicyloyltryptamine.
200mg/kg) and morphine (5mg/kg, i.p.) was also deter-
mined. An additional group pretreated with vehicle received
a similar volume of NST vehicle (tween 80 solution 0.2%).
2.4. Formalin-Induced Nociception. The formalin test was
carried out as described by Hunskaar and Hole [12]. Mice
were divided into ﬁve groups (n = 10, each) and treated
i.p. with vehicle (control), NST (100 and 200m/kg, i.p.),
and indomethacin (10mg/kg, i.p.). After 45min, 20μLo f
2.5%formalinsolution(0.92%formaldehydein0.9%saline)
was injected into the subplantar area of the right hindpaw.
The duration of paw licking was measured at 0–5min
(ﬁrst phase) and 15–30min (second phase) after formalin
administration.
2.5. Rota-Rod Test. Initially, the mice able to remain on
the Rota-rod (AVS, Brazil) longer than 210s (9rpm) were
selected 12 and 24h before the test [13, 14]. Then, the
selected animals were divided into four groups (n = 10) and
treated i.p. with vehicle (control), NST (100 and 200ml/kg,
i.p.), and diazepam (3mg/kg, i.p,). Thirty minutes later, each
animal was tested on the Rota-rod and the time(s) they
remained on the bar for up to 210s was recorded after 30,
60, and 90min.
2.6. Electrophysiologic Assays. Procedures for isolated nerve
experiments were fundamentally the same as described
in previous papers [15, 16]. In short, the sciatic nerves
of rats (Rattus norvegicus)w e r ec a r e f u l l yr e m o v e da n d
desheathed. One nerve bundle was positioned across the
ﬁve compartments of the experimental chamber, which
contained Vaseline at the partitions to electrically isolate
them. Compartments 1 and 2, at one end of the nerve
bundle,wereusedtoapplysupramaximalstimulation,which
consisted of 100 μs isolated rectangular voltage pulses (4–
6V), delivered by a stimulator (CF Palmer, Model 8048,
UK), triggered manually. These parameters were chosen to
selectively stimulate fast-conducting myelinated ﬁbers (Aα).
All compartments were ﬁlled with physiological solution
with the following composition (in mM): NaCl 150; KCl
4.0; CaCl2 2.0; MgCl2 1.0; [N-(2-hydroxyethyl) piperazine-
N -2-ethanesulfonic acid] (HEPES) 10, adjusted to pH 7.4
with NaOH, except for the fourth compartment, which
was ﬁlled with isotonic (280mM) sucrose solution that was
continuously renewed to electrically isolate the neighboring
recording compartments. The NST at concentration ofJournal of Biomedicine and Biotechnology 3
3.57mM was introduced into the test (central) compart-
ment. This concentration was chosen by the concentration-
response curve (data not shown). The potential diﬀerence
between the test and the ﬁfth (last) compartment was
recorded every 10min. Data were converted to digital form
by a microcomputer-based 12-bit A/D converter at a rate
of 10.5kHz and later analyzed using a suite of programs
(Lynux, S˜ ao Paulo, Brazil). To quantify the eﬀects of NST,
we used the amplitude (which is the potential diﬀerence
between the baseline and the maximal voltage of the
compound action potential—CAP), and the time constant
of repolarization (τ) that was calculated by the equation
V = V
∗





In vivo test. The data obtained were evaluated by one-way
analysis of variance (ANOVA) followed by Dunnett’s t or
Fisher’s Exact Tests.
In vitro test. For CAP recordings, the signiﬁcant level was
obtained using the two-tailed Student’s t-test. Diﬀerences
were considered to be statistically signiﬁcant when P<. 05.
The percent of inhibition caused by an antinociceptive
agent was determined for the acetic acid-induced writhing
and formalin tests through the following formula [17]:







In the acetic acid-induced writhing test, the antinociceptive
eﬀect, represented by writhe reduction, elicited by 100 and
200mg/kg of NST (14.1 ± 7.2 and 12.9 ± 6.3) in mice.
Morphine (5mg/kg) (1.3 ± 0.6) produced a reduction
of nociceptive response. In contrast, naloxone (1.5mg/kg,
i.p.), an opioid antagonist, showed no inﬂuence on the
antinociceptive action of NST (100 and 200mg/kg, i.p.)
(Table 1). The group that received only the diluent of
NST (tween 80 solution 0.2%) did not present signiﬁcant
behavioral alteration (data not shown).
Eﬀects of NST on formalin test are shown in Table 2.A l l
test groups are signiﬁcantly diﬀerent from control group on
the early and late phases (P<. 01). NST (100 and 200mg/kg,
i.p.) caused graded inhibition of both phases of formalin-
induced pain.
As shown in Table 3, the treatment of mice with NST
(100 and 200mg/kg, i.p.) did not show signiﬁcant motor
performance alterations (Table 3).
Figure 2 illustrates a typical example of the eﬀects of NST
(3.57mM)ontheCAPthatwasincubatedat30minshowing
decreased amplitude after NST incubation. This incubation
time was suﬃcient once that from 20min of NST addition,
we veriﬁed a stabilized eﬀect on the CAP amplitude. That
amplitude reduction produced by NST is shown in Figure 3.
Table 1: Eﬀect of NST or morphine on acetic acid-induced
writhing.
Treatment Dose (mg/kg) Number of
writhingsa % Inhibition
Vehicle — 39.4 ± 7.9 —
NST 100 14.1 ± 7.2c 64.2e
NST 200 12.9 ± 6.3c 67.3e
NST + naloxone 100 + 1.5 21.8 ± 7.7b 44.7e
NST + naloxone 200 + 1.5 18.1 ± 9.4b 50.1e
Morphine 5 1.3 ± 0.6d 96.7f
Morphine + naloxone 5 + 1.5 35.2 ± 5.8 10.7
n = 10 per group.
aValues represent mean ± S.E.M.
bP<. 05 (one-way ANOVA and Dunnett’s test), signiﬁcantly diﬀerent from
control.




eP<. 01 (Fisher’s test), signiﬁcantly diﬀerent from control.
fP<. 001 (Fisher’s test), signiﬁcantly diﬀerent from control.
Table 2: Eﬀect of NST or indomethacin on formalin-induced pain.
Treatment










Vehicle 92.3 ± 24.4 — 124.2 ± 23.1 —
NST
(100mg/kg) 43.8 ± 16.1b 52.5d 58.1 ± 17.3b 53.2d
NST
(200mg/kg) 39.9 ± 21.7b 56.8d 46.4 ± 13.2a 62.6d
Indomethacin
(10mg/kg) 78.4 ± 18.9 15.1 14.9 ± 8.9c 88.0e
n = 10 per group.
aValues represent mean [total time spent in licking (s)] ± S.E.M.
bP<. 05 (one-way ANOVA and Dunnett’s test), signiﬁcantly diﬀerent from
control.
cP<. 001 (one-way ANOVA and Dunnett’s test), signiﬁcantly diﬀerent from
control.
dP<. 01 (Fisher’s test), signiﬁcantly diﬀerent from control.
eP<. 001 (Fisher’s test), signiﬁcantly diﬀerent from control.
Table 3: Eﬀect of NST or diazepam on the Rota-rod test.
Treatment Time (s) on Rota-rod/210sa
30min 60min 90min
Vehicle 210.0 ± 0.0 195.3 ± 4.8 210.0 ± 0.0
NST (100mg/kg) 189.9 ± 5.1 181.5 ± 7.4 210.0 ± 0.0
NST (200mg/kg) 195.3 ± 5.8 210.0 ± 0.0 179.8 ± 9.3
Diazepam (3mg/kg) 38.7 ± 9.7b 17.2 ± 11.3b 23.5 ± 15.9b
The motor response was recorded for the following 210s after drug
treatment, n = 10, aValues represent mean ± S.E.M., bP<. 01 (one-way








Figure 2: Eﬀect of NST on nerve compound action potential
(CAP). The ﬁgure shows representative superimposed CAP record-
ings, in the absence (control, A) and 30min after the addition of
NST (3.57mM) (B).
Figure 4 shows the time constant of CAP repolarization
(τCAP) and during NST (3.57mM) incubation at 10, 30, and
40min the τCAP was decreased, showing a time-dependent
eﬀect that was stabilized after 20min of NST addition.
4. Discussion
In the past years, the discovery and development of central
analgesic drugs, non-opioid system, has been one of the
noticeable research ﬁelds. However, most antiepileptic drugs
currently used in therapy of epilepsy exhibit analgesic eﬀect
and are used in the treatment of chronic neuropathic pain
(trigeminalpain).Themaingoalofthisstudywastoevaluate
the possible antinociceptive eﬀect of the NST in rodents and
in sucrose-gap technique.
In the writhing test, doses of 100 and 200mg/kg of NST
signiﬁcantly reduced the number of writhing movements
induced by the i.p. administration of the acetic acid solution
(Table 1). This result indicates that the NST has antinocicep-
tiveactivity,butthistestisnonspeciﬁctodeterminethiskind
of activity, even though it can be widely used for analgesic
screening [18]. It was observed that naloxone (1.5mg/kg,
i.p.) antagonized the antinociceptive response of morphine
(standarddrug).However,naloxonedidnotreversetheeﬀect
of NST (100 and 200mg/kg, i.p.) (Table 1). That suggests the
nonparticipation of the opioid system in the modulation of
pain provoked by NST.
The formalin test is a valid and reliable model of
nociception and it is sensitive for several classes of analgesic
drugs. Formalin test produced a distinct biphasic response
and diﬀerent analgesics may act diﬀerently in the ﬁrst and
second phases of this test. Therefore, the test can be used
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Figure 3: Eﬀect of NST (3.57mM) on the CAP amplitude. This
ﬁgure shows the time-course of NST incubation. The bars indicate
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Figure 4: Eﬀe c to fN S T( 3 . 5 7 m M )o nt h et i m ec o n s t a n to f
CAP repolarization. This ﬁgure shows the time-course of NST
incubation. The bars indicate the mean ± S.E.M. of 5 experiments.
∗P<. 05 in relation to absence of NST addition.
of a proposed analgesic [19]. Centrally acting drugs such as
opioidsinhibitbothphasesequally[20],butperipherallyact-
ingdrugssuchasaspirin, indomethacin, anddexamethasone
only inhibit the late phase [12]. The late phase seems to be an
inﬂammatory response with inﬂammatory pain that can be
inhibited by anti-inﬂammatory drugs [12, 13]. The eﬀect of
NST on the ﬁrst and second phases (Table 2)o ff o r m a l i nt e s t
suggests that its activity may result from its central action,
but without the opioid system participation.
Previous studies suggested that the CNS depression and
the nonspeciﬁc muscle relaxation eﬀect can reduce the
response of motor coordination and, consequently, might
invalidate the formalin test results [13, 14]. As Oliveira
et al. [10] showed depressant eﬀect on the CNS in mice
treated with NST, we realized motor coordination test (Rota-
rod). Our results demonstrated that NST-treated (100 and
200mg/kg, i.p.) mice showed no performance alterations
in the Rota-rod test with the doses used (Table 3). We did
not see any motor coordination change for the animals,Journal of Biomedicine and Biotechnology 5
therefore, eliminating a nonspeciﬁc muscle relaxation eﬀect
of NST at the doses used.
In this study, the reduction of CAP amplitude induced by
NST suggests a voltage-gated sodium channel blocker. Some
anticonvulsant agents, used in trigeminal pain, have shown
a mechanism that involves a participation of the voltage-
gatedsodiumchannels[3].Similarlytoourﬁndings,Oliveira
et al. [10] have showed that NST possesses anticonvulsant
property in mice and Machado Ara´ ujo et al. [21]h a v e
demonstrated that NST promotes the blockade of sodium
channels from GH3 cells. However, the alteration produced
by NST on the time constant of repolarization could also
indicate a possible involvement of voltage-gated potassium
channels as it was veriﬁed by Pisciotta and Prestipino [22]
when fenitoine was used. Moreover, an analgesic eﬀect was
described for lamotrigine, felbamate, gabapentin, and anti-
convulsant drugs in cold allodynia test (chronic constriction
injury model) [23].
Based on our results, N-salicyloyltryptamine (NST)
has antinociceptive activity that may be associated with
decreased peripheral nerve excitability. The precise mech-
anisms underlying the inhibitory eﬀect of NST are not
clear. However, its antinociceptive property might involve a
voltage-gated sodium channel blocker and nonparticipation
of the opioid system. Moreover, these results also support
that NST has a therapeutic potential for painful disorders.
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